Why JPMorgan Chase, Pfizer, and Goldman Sachs Were the Dow's Worst Stocks Last Week

The Dow had a pretty sizable correction last week, pulling down all but a handful of stocks. Find out why these three got hit hard.

Apr 12, 2014 at 5:00PM

Two straight days of triple-digit declines, including a massive 267-point drop on Thursday, helped pull Dow Jones Industrials (DJINDICES:^DJI) down about 2.4% for the week. With the Dow having gone so long without a major pullback, investors have been a bit trigger-happy about selling at the slightest hint of trouble ahead, and that sentiment was evident over the past week, especially among high-flying sectors like biotechnology and social media. For the Dow, though, JPMorgan Chase (NYSE:JPM), Pfizer (NYSE:PFE), and Goldman Sachs (NYSE:GS) were the worst performers of the week, with all three falling between 6% and 8%. Let's take a closer look at why these three stocks led the losers' list.


JPMorgan Chase's earnings report on Friday morning got the lion's share of attention not just for investors in the bank but across the stock market, as its troubling report emphasized the struggle that CEO Jamie Dimon and his management team will face in trying to keep growth at reasonable levels. Plunging earnings across its business lines suggested that JPMorgan might have nowhere to hide, yet the stock actually lost more ground on Thursday before its earnings report. JPMorgan Chase will have to deal with higher capital requirements and tougher regulation as well as a Republican-proposed big-bank tax, all the while dealing with an economic environment in which businesses have free access to capital markets directly without going through banks. Shares are still valued cheaply, but JPMorgan Chase needs to give investors a solid strategy going forward to regain its recent record-setting levels.

Pfizer's drop came amid general disdain for biotech and pharmaceutical stocks generally, but news of a study that could potentially link Viagra use with greater risk of melanoma helped add to the drug giant's declines. The study is an early stage look at the issue, and even the researchers themselves admitted that further scrutiny would be necessary before anyone should draw definitive conclusions about Viagra and the severe skin cancer. The news made investors largely ignore positive data from a mid-stage study of Pfizer's palbociclib, which has the potential to become a blockbuster breast-cancer treatment. With huge amounts of legal liability against various drug companies with similar problems in the past, Pfizer has to manage its risk to avoid what could become a much bigger problem down the road.


Goldman's declines came from many of the same factors that held back JPMorgan this week, including the coming 5% minimum capital requirement on big banks. Indeed, many investors expect Goldman Sachs to suffer even steeper drops than JPMorgan did when it reports its own quarterly results next week, as it has struggled to try to make its profitability recover toward post-crisis levels. Unless surprisingly low rates spur more activity in the bond market, which is a bastion of strength for Goldman Sachs, it could be problematic for Goldman to get back its former glory -- especially as regulators tighten their grip on the industry.

Big banking's little $20.8 trillion secret
There's a brand-new company that's revolutionizing banking, and is poised to kill the hated traditional brick-and-mortar banks. That's bad for them, but great for investors. And amazingly, despite its rapid growth, this company is still flying under Wall Street's radar. To learn about about this company, click here to access our new special free report.

Dan Caplinger owns warrants on JPMorgan Chase. The Motley Fool recommends Goldman Sachs and owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers